Johnson & Johnson to Buy Abiomed for $16.6B

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Nov 1, 2022 at 11:22 AM.

  1. #1 cafead, Nov 1, 2022 at 11:22 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via Johnson & Johnson just revved up its M&A engine in a big way.

    The New Brunswick, NJ-based company plans to acquire Abiomed in a deal valued at about $16.6 billion ($380 a share), which includes cash acquired. Abiomed shareholders will also receive a non-tradeable contingent value right to receive up to $35 a share in cash if certain commercial and clinical milestones (noted below) are achieved. The deal price is a 50% premium to Monday's closing stock price.

    article source
     
    Quote

  2. #2 anonymous, Nov 1, 2022 at 6:39 PM
    anonymous

    anonymous Guest

    Everything J&J touches turns into SH%T. Let's the demise of culture and people begin...
     
    Quote
Reply to Thread